← All trials
NCT04542213
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 1, 2020
- Primary completion
- Sep 30, 2020
- Completion date
- Sep 30, 2020
- First posted
- Sep 9, 2020
- Last posted
- Sep 9, 2020
- Enrollment
- 28
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Hospital Regional Alta Especialidad BajioLead sponsor
- Hospital Regional Alta Especialidad BajioReponsible party - principal investigator
- Hospital Regional Alta Especialidad BajioOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.